DelveInsight’s, “Proto Oncogene Proteins C PIM 1 Inhibitors – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Proto Oncogene Proteins C PIM 1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Proto Oncogene Proteins C PIM 1 Inhibitors: Overview
PIM (proviral integration site for moloney murine leukemia virus) kinase plays a key role as an oncogene in various cancers including myeloma, leukemia, prostate and breast cancers. The PIM kinases, which constitute a class of serine/threonine kinase, act as oncoproteins and promote cell survival by transcriptional activation of genes involved in cell proliferation. The family of PIM kinase consists of three isoforms, PIM-1, PIM-2, and PIM-3. Each of the PIM kinases plays an important role in tumorigenesis. While PIM-1 has been reported to be over-expressed in several hematological and solid tumors PIM-2 is highly expressed in myeloma, lymphoma and leukemia. The elevated expression of PIM-3 has been noted in adeno-carcinomas. Diverse roles that the PIM kinases play in carcinogenesis include multiple myeloma proliferation, anti- apoptosis, cell cycle modulation, and mediating bone destruction. PIM kinases have been well studied as a potential therapeutic target for developing anti-cancer drugs due to their pivotal roles in cancers.
"Proto Oncogene Proteins C PIM 1 Inhibitors - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proto Oncogene Proteins C PIM 1 Inhibitors pipeline landscape is provided which includes the disease overview and Proto Oncogene Proteins C PIM 1 Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Proto Oncogene Proteins C PIM 1 Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proto Oncogene Proteins C PIM 1 Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Proto Oncogene Proteins C PIM 1 Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Proto Oncogene Proteins C PIM 1 Inhibitors.
This segment of the Proto Oncogene Proteins C PIM 1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Proto Oncogene Proteins C PIM 1 Inhibitors Emerging Drugs
MEN 1703: Menarini Group
MEN1703 is a dual kinase inhibitor targeting PIM (PIM1, PIM2, and PIM 3) and FLT3 kinases. FLT3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in acute myeloid leukemia patients (AML) and is associated with a poor prognosis. PIM kinases are thought to be one of the major drivers of the resistance phenotype to FLT3 inhibitors and their inhibition in relapsed samples restores cell sensitivity to FLT3 inhibitors these agents. The spectrum of activity of MEN1703 also warrants the compound investigation in AML patients regardless of FLT3 aberrations. MEN1703 is being investigated as potential treatment for adult patients with relapsed/refractory AML in Phase II clinical trial.
Further product details are provided in the report……..
This segment of the report provides insights about the different Proto Oncogene Proteins C PIM 1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 5+ key companies which are developing the therapies for Proto Oncogene Proteins C PIM 1 Inhibitors. The companies which have their Proto Oncogene Proteins C PIM 1 Inhibitors drug candidates in the most advanced stage, i.e. phase II include Menarini Group.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
Proto Oncogene Proteins C PIM 1 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Proto Oncogene Proteins C PIM 1 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto Oncogene Proteins C PIM 1 Inhibitors drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Proto Oncogene Proteins C PIM 1 Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Mid Stage Products (Phase II)
MEN 1703: Menarini Group
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Uzansertib: Incyte Corporation
Drug profiles in the detailed report…..
Inactive Products
Proto Oncogene Proteins C PIM 1 Inhibitors Key Companies
Proto Oncogene Proteins C PIM 1 Inhibitors Key Products
Proto Oncogene Proteins C PIM 1 Inhibitors- Unmet Needs
Proto Oncogene Proteins C PIM 1 Inhibitors- Market Drivers and Barriers
Proto Oncogene Proteins C PIM 1 Inhibitors- Future Perspectives and Conclusion
Proto Oncogene Proteins C PIM 1 Inhibitors Analyst Views
Proto Oncogene Proteins C PIM 1 Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Proto Oncogene Proteins C PIM 1 Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Proto Oncogene Proteins C PIM 1 Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Tolero Pharmaceuticals
• Novartis
• Inflection Biosciences/AUM Biosciences
• Menarini
• Incyte Corporation
• AstraZeneca
